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Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract. In this issue
of Immunity, Griseri et al. (2012) show that IL-23-induced dysregulation of hematopoietic stem and progenitor
cells contributes to the pathogenesis of two IBD models.Crohn’s disease (CD) and ulcerative
colitis are the two major forms of inflam-
matory bowel disease (IBD). For many
years, researchers have studied patho-
genic mechanisms of IBD by using ex-
perimental animal models. Interleukin-10
(IL-10)-deficient mice and IL-2-deficient
mice, in which Tr1 and Foxp3+ regulatory
T (Treg) cells, respectively, are absent,
spontaneously develop colitis resembling
CD. Administration of dextran sulfate
sodium (DSS) damages the epithelial
layer of the intestine and allows intestinal
commensal bacteria to invade, resulting
in the induction of acute colitis and rapid
transient weight loss. Helicobacter hepa-
ticus (H. hepaticus) infection induces
IBD-like lesion in Rag1/ mice. Rag1/
mice that have received a transfer of
naive CD4+CD25-CD45RBhi T cells also
develop wasting disease and colitis
resembling the IBD that occurs in hu-
mans. Type 1 helper T (Th1) cells had
been implicated in the pathogenesis of
this model of IBD because more than
half of helper T cells produced IFN-g and
treatment with anti-IFN-g or anti-IL-
12p40 alleviated the inflammation. How-
ever, using an IL-10-deficient mouse
colitis model, Yen et al. (2006) demon-
strated the importance of IL-23, a cytokine
consisting of the IL-23-specific p19 sub-
unit and the IL-12p40 subunit, in the
development of the disease. The develop-
ment of colitis was suppressed by the
deficiency of p19 but not by that of p35,
an IL-12-specific subunit, indicating that
the IL-23-driven axis, but not the IL-12-
Th1 axis, is important for the development
of colitis. Through direct signaling into
T cells, IL-23 drives intestinal T cell pro-
liferation, promotes intestinal Th17 cell
accumulation, and enhances the emer-
gence of IL-17A+IFN-g+ CD4+ T cell pop-
ulation (Ahern et al., 2010). IL-23 receptorsignaling in intestinal T cells suppresses
the differentiation of Foxp3+ Treg cells
and IL-10 production by Tr1 cells (Ahern
et al., 2010). Furthermore, several poly-
morphisms in the IL-23R gene locus
have been found to be associated with
susceptibility to intestinal inflammation
by genome-wide association studies in
cohorts of IBD patients (Morrison et al.,
2011). These observations suggest that
IL-23 also plays an important role in
disease pathogenesis in humans.
In this issue of Immunity, Griseri et al.
demonstrate a function of IL-23 in
the development of CD45RBhi-T-cell-
induced and H. hepaticus-induced colitis.
They show that proliferating hematopoi-
etic stem cells (HSCs) accumulate in
the bone marrow (BM) and spleen and
that granulocyte-monocyte progenitor
(GMP) production is enhanced in the
intestine. Blockade of granulocyte macro-
phage-colony stimulating factor (GM-
CSF) reduces the accumulation of splenic
and colonic GMPs, resulting in ameliora-
tion of colitis. Furthermore, transfer of
GMPs exacerbates colitis. Thus, HSPCs
are suggested to be a major target
of the IL-23-driven inflammatory axis
(Figure 1).
Because IL-17A production was greatly
reduced in IL-23 p19-deficient mice and
because treatment with anti-IL-17A and
anti-IL-6, but not anti-IL-17A or anti-IL-6
alone, suppressed the development of
colitis in IL-10-deficient mice, it was sug-
gested that the IL-23-IL-17 axis was
important for the development of colitis
(Yen et al., 2006). Th17 cells are enriched
in the inflamed gut both in animal models
and in human cases, and T cells lacking
the retinoic-acid-related orphan receptor
(RORgt), a transcription factor that directs
Th17 cell differentiation, cannot transfer
colitis to Rag1/ mice. H.-hepaticus-Immunity 37, Ddriven innate colitis is associated with an
increased production of IL-17A and IFN-
g in the colon, and treatment with anti-
IL-17A or anti-IFN-g can suppress the
development of colitis (Buonocore et al.,
2010). The production of IL-17A and
IFN-g is induced by IL-23 mainly from
innate lymphoid cells expressing Thy1,
Sca-1, RORgt, and IL-23R, and these
cells markedly accumulate in the in-
flamed colon. The fact that
Rag1/Rorc/ mice failed to develop
colitis indicates that RORgt, which
controls IL-23R expression and Th17 cell
differentiation, is important. Administra-
tion of anti-IL-17A ameliorates the colitis
developed in mice bearing a conditional
deletion of Stat3 in Treg cells. A recent
study also suggests the involvement of
IL-17A in the pathogenesis of H.-hepati-
cus-triggered colitis and naive-T-cell-
transfer colitis, in which excess IL-1b
signaling in collaboration with IL-23
promotes the accumulation of IL-17A-
secreting innate lymphoid cells and Th17
cells in the intestines (Coccia et al.,
2012). The importance of Th17 cells is
also shown in a colitis model in which
T cells from a T cell receptor transgenic
mouse specific for an immunodominant
microbiota flagellin are transferred into
TCRb- and TCRd-deficient mice. How-
ever, the role of IL-17A in the development
of IBD is controversial. In the DSS-
induced colitis model, Il17a/ mice
show increased pathology and leukocyte
infiltration, suggesting a protective role
of IL-17A. The deficiency of IL-17A did
not suppress the development of colitis
in the naive-T-cell-transfer model (Izcue
et al., 2008). Furthermore, O’Connor
et al. (2009) showed that IL-17A is rather
protective in the model of colitis induced
by CD45RBhi T cell transfer. IL-17A-defi-
cient T cells elicit an accelerated wastingecember 14, 2012 ª2012 Elsevier Inc. 957
Figure 1. IL-23-Driven Colitis in which Hematopoietic Disregulation Plays an Important Role
CD4+CD25CD45RBhi naive T cell transfer or H. hepaticus infection induces IBD-like colitis in Rag1/
mice. Th17-cell-inducing cytokines, such as TGF-b, IL-6, and IL-1, are produced by DCs or macrophages
upon interaction with commensal microbiota in the intestine, and naive T cells differentiate into Th17 cells
after interaction with microbial antigens under Treg-cell-insufficient conditions. IL-23 produced by intes-
tinal innate immune cells further differentiate Th17 cells into polyfunctional Th17 cells that produce IFN-
g+IL-17A, GM-CSF+IFN-g+IL-17A, or IFN-g (ex-Th17). These polyfunctional Th17 cells produce IFN-g
in the BM and spleen to enhance proliferation and hematopoietic activity of LT-HSCs. Furthermore,
GM-CSF from these cells promotes differentiation and proliferation of GMPs in the colon and spleen
and induces accumulation of neutrophils and monocytes in the colon, causing inflammation by producing
inflammatory mediators such as TNF or IL-1.
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type cytokines and polarization of Th1
cells. IL-17R-deficient mice also develop
an accelerated, aggressive wasting
disease (O’Connor et al., 2009). Therefore,
the pathogenic role of the IL-23-IL-17 axis
in colitis is not clear at present, and the
reason for these conflicting results is not
yet known. Because commensal micro-
floa in the intestine affect the development
of colitis and because both IL-17A and
IL-17F are important for anti-microbial
activity, further investigation, including
that of the pathogenic roles of microflora
in the intestine, is needed to elucidate
the roles of IL-17A and IL-17F in the devel-
opment of IBD.
In IL-23-dependent colitis models such
as those involving CD45RBhi T cell trans-
fer or H. hepaticus infection, excessive
accumulation of myeloid cells, especially
neutrophils and inflammatory monocytes,
is observed in the colon (Morrison et al.,
2011). Accumulation of neutrophils that
can secrete various inflammatory media-
tors such as proinflammatory cytokines,
chemokines, proteases, and reactive
oxygen species correlates with clinical
disease activity, and the amount of fecal
calprotectin (a predominant component
of neutrophil cytosol) is a clinical marker
in IBD. In addition, high numbers of
inflammatory monocytes and macro-958 Immunity 37, December 14, 2012 ª2012phages are present in the inflamed intes-
tine in CD patients. However, the precise
roles of these cells in the pathogenesis
of IBD and the regulation of innate cell
accumulation in the inflamed intestinal
mucosa are poorly understood.
Griseri et al. (2012) elucidated the
mechanisms of how inflammatory mye-
loid cell accumulation in intestinal mucosa
is regulated by HSPCs and GMPs at the
BM and spleen during colitis and identi-
fied IFN-g and GM-CSF as two critical
colitogenic cytokines downstream of IL-
23. IFN-g is a well-known colitogenic
cytokine that is increased in the colon
and serum of colitic mice (Ahern et al.,
2010), and its secretion by pathogenic
Th1, Th17, and innate lymphoid cells is
promoted by IL-23 (Ahern et al., 2010;
Buonocore et al., 2010). Griseri et al.
show that blockade of IFN-g diminished
the increase of LinSca1+c-kithi HSC in
the BM and spleen, as well as the
long-term increase of HSC in the BM in
H.-hepaticus- and naive-T-cell-induced
colitis. In the diseased mice, IFN-g-
producing T cell accumulation was found
not only in the spleen and colon but also in
the BM, suggesting direct control of HSC
by these cells. Thus, IFN-gmight exert its
pathogenic role in colitis not only by
promoting effector functions in mature
leukocytes but also by boosting theElsevier Inc.hematopoietic activity at the level of the
primordial HSCs. Furthermore, Griseri
et al. showed that administration of
anti-GM-CSF inhibits the peripheral accu-
mulation of GMPs and attenuates intes-
tinal inflammation in T-cell-transfer colitis.
GMP percentages and total numbers
were significantly decreased in the
spleen of T-cell-transferred mice injected
with anti-GM-CSF. Adoptive transfer
of splenic GMPs isolated from colitic
mice into Rag1/mice that had received
naive T cells 2 weeks before enhanced
disease. Thus, in addition to contributing
to increased granulopoiesis in the BM,
GMPs also accumulate in the inflamed
spleenandcolon,where theyplayapatho-
genic role probably by sustaining the local
accumulation of neutrophils and inflam-
matory monocytes (Figure 1). Although
these IFN-g producer cells and GM-CSF
producer cells are likely to be IFN-g+IL-
17A+ Th17 cells and GM-CSF+IFN-g+IL-
17A+ Th17 cells, respectively, their identi-
ties remain to be confirmed.
So far, the role of HSCs and GMPs in
the chronicity of inflammatory diseases
has been overlooked. However, the
importance of these stem cells has been
highlighted recently. Dutta et al. (2012)
used Apoe/ mice to show that athero-
sclerosis is accelerated after myocardial
infarction or stroke. This is because
myocardial infarction liberates HSCs and
GMPs from BM niches. The progenitors
then seed the spleen, yielding a sustained
boost in monocyte production. Kim et al.
(2011) also showed that Staphylococcus
aureus infection elicits mobilization of
polymorphonuclear neutrophils (PMNs)
from the BM to the infected wound. A
continuous rise in wound neutrophil
number is correlated with the homing of
c-kit+ progenitor cells from the blood to
the wound, where they proliferate and
formmature PMNs. Blocking their recruit-
ment limits the proliferation of mature
PMNs and shortens mouse survival.
Collectively, HSPCs and GMPs play
important roles in chronic inflammatory
diseases and host defense against infec-
tion, suggesting therapeutic strategies
for the treatment of these diseases.REFERENCES
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